{"entity":{"id":"mightytil","kind":"drug","name":"MightyTIL","aka":["MightyTIL (TrAMPoline Pharma)"],"tldr":"MightyTIL is an experimental cell treatment from TrAMPoline Pharma that strengthens immune cells taken from a patient's own tumour. It is in laboratory testing.","summary":"MightyTIL is the lead candidate of TrAMPoline Pharma, an autologous gene-engineered TIL product for sarcoma, head and neck cancer and melanoma. The company reports higher potency, persistence and lower IL-2 needs than unmodified TIL in preclinical studies. No clinical data exist.","status":"preclinical","asOf":"2026-11-04","links":[{"label":"TrAMPoline Pharma","url":"https://www.trampolinepharma.com/"}],"tags":["pipeline"],"related":[],"cancers":[],"sections":[],"technologies":["til-therapy"],"targets":[],"drugs":[],"companies":["trampoline-pharma"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo startup monitors","editedOn":"2026-11-04"},"modality":"Gene-engineered tumour-infiltrating lymphocyte therapy","mechanism":"Tumour-infiltrating lymphocytes engineered with coR8:Amp, which the developer says strengthens T cell receptor binding to cancer cells and T cell receptor signalling.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/mightytil/","neighbours":{"technology":[{"id":"til-therapy","kind":"technology","name":"TIL therapy","route":"/technologies/til-therapy/"}],"company":[{"id":"trampoline-pharma","kind":"company","name":"TrAMPoline Pharma","route":"/companies/trampoline-pharma/"}]}}